Paroxetine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002319/202212

Paroxetine : List of nationally authorised medicinal products - PSUSA/00002319/202212

Day 80 assessment report - Overview and D120 LOQ template with guidance - Rev. 10.23

Day 150 or Day 195 joint response assessment report - Overview and list of outstanding issues template - Rev. 10.23

Human medicines European public assessment report (EPAR): Mavenclad, cladribine, Multiple Sclerosis, Date of authorisation: 22/08/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Sunosi, solriamfetol, Narcolepsy;Sleep Apnea, Obstructive, Date of authorisation: 16/01/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Pain;Cancer, Date of authorisation: 20/07/2009, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, HIV Infections, Date of authorisation: 19/03/2001, Revision: 61, Status: Authorised

Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Candidiasis;Aspergillosis, Date of authorisation: 23/10/2001, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Lytgobi, futibatinib, Cholangiocarcinoma, Date of authorisation: 04/07/2023, Revision: 1, Status: Authorised